| Factor Information | |
|---|---|
| Data ID | 410 |
| Factor | Patients with Fontan palliation or Eisenmenger physiology (%) |
| Description | The percent of patients with Fontan palliation or Eisenmenger physiology in the CHD with MACE was significant higher than that in the CHD without MACE. |
| Biomarker | NA |
| Classification | A3 (clinical factor - disease & symptom) |
| Association | |
|---|---|
| Application | prognosis |
| Objective | To assess the percent of patients with Fontan palliation or Eisenmenger physiology between the CHD with and without MACE. |
| p Value | 0.004 |
| Conclusion | The percent of patients with Fontan palliation or Eisenmenger physiology in the CHD with MACE was significant higher than that in the CHD without MACE. |
| Risk Factor | unknown |
| CHD Type | |
|---|---|
| ID | 448 |
| CHD Type | isolated CHD/non-isolated CHD |
| CHD Subtype | CRHD/other/SRV/EIS/complex CHD |
| Reference | |
|---|---|
| PMID | 30118521 |
| Year | 2018 |
| Title | Predictive value of soluble ST2 in adolescent and adult patients with complex congenital heart disease. |
| Sample | ||
|---|---|---|
| Population | consecutive patients with complex CHD | |
| Source | Blood | |
| Region | Homburg/Saar,Germany | |
| Method | In all participants, venous blood samples were drawn into standard sampling tubes after echocardiography. | |
| Race | Europe | |
| Disease History | N/A | |
| Treatment History | N/A | |
| Group | patients with major adverse cardiac enent, MACE(Treatment) | patients without major adverse cardiac enent, MACE(Control) |
| Number | 13(total:17) | 58(total:152) |
| Age | 27.9 ± 13.9 years | 28.3 ± 11.8 years |
| Gender (Male: Female) | N/A | N/A |
| Marker Level | 0.765 | 0.382 |
